TRCT
PMN icon

Tower Research Capital (TRC)’s ProMIS Neurosciences PMN Stock Holding History

Tower Research Capital (TRC)’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20
Closed -$136 – 5456
2025
Q4 		$136 Buy
+20
New +$195 ﹤0.01% 5019

Other funds holding PMN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM

Tower Research Capital (TRC)'s PMN Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of ProMIS Neurosciences (PMN) in Q1 2026, closing a stake of 20 shares — an estimated $136 sold.

Tower Research Capital (TRC) first reported a position in PMN in Q4 2025 and held it in 1 quarter. The position peaked at $136 in Q4 2025. 25 funds tracked by Wall St. Rank hold PMN as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining ProMIS Neurosciences position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 20 ProMIS Neurosciences shares in Q1 2026, an estimated $136.
  • Tower Research Capital (TRC) first reported a position in ProMIS Neurosciences in Q4 2025 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s ProMIS Neurosciences position peaked at $136 in Q4 2025.
  • 25 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.